DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages
Author: Jane Morgan MB ChB MRCP FACSHP, Sexual Health Physician, Hamilton, New Zealand, 2003. Updated by Hon A/Prof Amanda Oakley, September 2015.
An anogenital wart is a common superficial skin lesion in the anogenital area that is caused by human papillomavirus (HPV). Anogenital warts are also called condyloma acuminata, genital warts, venereal warts and squamous cell papilloma.
The human papillomavirus (HPV) is actually a group of double-stranded DNA viruses.
As anogenital warts are sexually acquired during close skin contact, they are most commonly observed in young adults between the ages of 15 and 30 years. They are highly contagious, and occur in equal numbers in unvaccinated males and females. However, they are rare in people that have been vaccinated against HPV in childhood before beginning sexual activity.
An anogenital wart is a flesh coloured papule a few millimetres in diameter. Warts may join together to form plaques up to several centimetres across.
They may occur in the following sites:
Warts due to the same types of HPV can also arise on the lips or within the oral mucosa.
Normal anatomical structures may be confused with warts. These include:
Visible genital warts and subclinical HPV infection nearly always arise from direct skin to skin contact.
Often, warts will appear three to six months after infection but they may appear months or even years later.
Transmission of warts to a new sexual partner can be reduced but not completely prevented by using condoms. Condoms do not prevent all genital skin-to-skin contact, but they also protect against other STDs.
Successful treatment of the warts decreases the chance of passing on the infection.
Genital warts are usually diagnosed clinically.
Biopsy is sometimes necessary to confirm the diagnosis or viral wart or to diagnose an associated cancer.
In some circumstances, researchers and clinicians may wish to confirm the presence or absence of HPV. One commercially available qualitative test for HPV is the COBAS 4800 Human Papillomavirus (HrHPV) Test, which evaluates 14 high-risk (HR oncogenic) HPV types. A negative test excludes high-risk infection.
The primary goal of treatment is to eliminate warts that cause physical or psychological symptoms such as:
The underlying viral infection may persist after the visible warts have cleared. Warts sometimes re-emerge years later because the immune system has weakened.
To be successful the patient must identify and reach the warts, and follow the application instructions carefully. Available treatments include:
in-clinic treatments include:
Experimental therapies for genital warts include:
The HPV types that cause external visible warts (HPV Types 6 and 11) rarely cause cancer. Other HPV types (most often Types 16, 18, 31, 33 and 35) are less common in visible warts but are strongly associated with anogenital cancer, including:
HPV also causes some cases of oral and nasopharyngeal cancer.
Only a small percentage of infected people develop genital cancer. This is because HPV infection is only one factor in the process; cigarette smoking and how well the immune system is working are also important.
Cervical smears, as recommended in the National Cervical Screening guidelines, detect squamous intraepithelial lesions of the cervix, which can be treated. If these abnormalities were ignored over a long period, they could progress to cervical cancer.
Several vaccines are available to prevent HPV infection.
HPV vaccination is most effective when offered at a young age, before the onset of sexual activity. However, girls that are already sexually active may not have been infected with the types of HPV covered by the vaccine and may still benefit from vaccination. Women that receive HPV vaccine should continue to participate in cervical screening programmes, as about 30% of cervical cancers will not be prevented by the vaccine.
HPV vaccines are also effective in boys. Vaccination of boys is recommended to reduce transmission of HPV to unvaccinated females. It also reduces the incidence of cancers related to HPV infection.
There has been interest in developing therapeutic HPV vaccines for the treatment of genital warts and cervical cancer in those already infected, and for other strains of HPV that are associated with other forms of viral warts.
See the DermNet NZ bookstore.
© 2019 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.